GSK3B and early-onset autosomal dominant Alzheimer disease: On the other hand, therapies aiming to activate Wnt signaling, including DKK-neutralizing antibodies or GSK3β kinase inhibitors, have been considered for treatment of diseases with reduced Wnt signaling such as Alzheimer’s disease (40, 42).